Which of these complications of insulin therapy is characterized by a rapid decrease in serum glucose, usually at night, causing the release of glucose-elevating hormones and an elevated glucose level in the morning, which may be inadvertently treated with an increased insulin dose?

Choice A rationale: The Dawn phenomenon is a morning hyperglycemia that results from the normal circadian release of growth hormone and cortisol. These hormones increase glucose production in the liver, leading to elevated blood glucose levels. Unlike the Somogyi phenomenon, it is not preceded by a nocturnal hypoglycemic episode. Choice B rationale: Insulin resistance is a physiological condition in which cells fail to respond to the normal actions of insulin. The body's cells do not effectively absorb glucose, leading to elevated blood glucose levels. It is a chronic condition and does not involve an acute nocturnal hypoglycemic event followed by a rebound hyperglycemia. Choice C rationale: Lipodystrophy is a complication of insulin therapy characterized by changes in subcutaneous fat tissue at injection sites. It can present as either lipoatrophy (denting of the skin) or lipohypertrophy (thickening of the skin). This is a localized skin condition and not a systemic metabolic phenomenon related to blood glucose fluctuations. Choice D rationale: The Somogyi phenomenon is a rebound hyperglycemia that occurs after an episode of undetected hypoglycemia, typically overnight. The low glucose triggers the release of counter-regulatory hormones (glucagon, epinephrine, cortisol, and growth hormone) which stimulate the liver to release glucose, leading to an elevated morning blood glucose level.